Traws Pharma Inc (TRAW)

$2.04 0.00 (N/A)
Market Cap 16.86M
Revenue (ttm) 230,000.00
Net Income (ttm) -166.52M
EPS (ttm) N/A
PE Ratio 0.02
Forward PE N/A
Profit Margin -72,400.00%
Debt to Equity Ratio 0.00
Volume 22,900
Avg Vol 349,926
Day's Range N/A - N/A
Shares Out 7.99M
Stochastic %K 12%
Beta 1.66
Analysts Strong Sell
Price Target $8.00

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
Schube1255
Schube1255 Feb. 2 at 11:58 PM
$TRAW yes , for a friggen year
0 · Reply
jstocks100
jstocks100 Feb. 2 at 3:59 PM
$TRAW
0 · Reply
Johnny_Drama
Johnny_Drama Jan. 30 at 5:45 PM
$TRAW Did they reopen the recruitment for Ratutrelvir? This showed as "Completed" as of yesterday. Study timelines have been updated as well...
2 · Reply
Dwarn2021
Dwarn2021 Jan. 29 at 3:53 PM
$TRAW Somebody bought up 6.8% in January for their family office :) https://www.sec.gov/Archives/edgar/data/1130598/000204207726000007/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Dwarn2021
Dwarn2021 Jan. 28 at 3:18 PM
$TRAW fantastic buying opportunity here, IMO!
0 · Reply
Dwarn2021
Dwarn2021 Jan. 27 at 7:05 PM
$TRAW 2026 - the year of increased M&A (down to small and micro-caps with promising pipelines) rapid advancements in drug discovery, and faster approvals from the FDA. Extremely bullish. The big players need to find revenue replacements for the approaching patent cliff.
0 · Reply
Schube1255
Schube1255 Jan. 27 at 4:15 PM
$TRAW halted up again?
1 · Reply
Jbjb90
Jbjb90 Jan. 27 at 1:45 PM
$TRAW sooner or later the roof is going go blow off this thing
0 · Reply
jstocks100
jstocks100 Jan. 27 at 1:39 PM
$TRAW 📈
0 · Reply
Titi_Valk
Titi_Valk Jan. 27 at 12:43 PM
$TRAW https://www.rttnews.com/3613578/traws-pharma-completes-enrollment-in-phase-2-study-of-ratutrelvir-expands-txm-to-influenza.aspx woooow
0 · Reply
Latest News on TRAW
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Jan 13, 2026, 7:00 AM EST - 22 days ago

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 30, 2025, 12:00 PM EDT - 3 months ago

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 22, 2025, 6:40 PM EDT - 3 months ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 1:14 PM EDT - 6 months ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Aug 8, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 7 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 8 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 9 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 11 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 11 months ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 11 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 11 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 1 year ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 2 years ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 2 years ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 8:18 PM EST - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Schube1255
Schube1255 Feb. 2 at 11:58 PM
$TRAW yes , for a friggen year
0 · Reply
jstocks100
jstocks100 Feb. 2 at 3:59 PM
$TRAW
0 · Reply
Johnny_Drama
Johnny_Drama Jan. 30 at 5:45 PM
$TRAW Did they reopen the recruitment for Ratutrelvir? This showed as "Completed" as of yesterday. Study timelines have been updated as well...
2 · Reply
Dwarn2021
Dwarn2021 Jan. 29 at 3:53 PM
$TRAW Somebody bought up 6.8% in January for their family office :) https://www.sec.gov/Archives/edgar/data/1130598/000204207726000007/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Dwarn2021
Dwarn2021 Jan. 28 at 3:18 PM
$TRAW fantastic buying opportunity here, IMO!
0 · Reply
Dwarn2021
Dwarn2021 Jan. 27 at 7:05 PM
$TRAW 2026 - the year of increased M&A (down to small and micro-caps with promising pipelines) rapid advancements in drug discovery, and faster approvals from the FDA. Extremely bullish. The big players need to find revenue replacements for the approaching patent cliff.
0 · Reply
Schube1255
Schube1255 Jan. 27 at 4:15 PM
$TRAW halted up again?
1 · Reply
Jbjb90
Jbjb90 Jan. 27 at 1:45 PM
$TRAW sooner or later the roof is going go blow off this thing
0 · Reply
jstocks100
jstocks100 Jan. 27 at 1:39 PM
$TRAW 📈
0 · Reply
Titi_Valk
Titi_Valk Jan. 27 at 12:43 PM
$TRAW https://www.rttnews.com/3613578/traws-pharma-completes-enrollment-in-phase-2-study-of-ratutrelvir-expands-txm-to-influenza.aspx woooow
0 · Reply
sergyo11
sergyo11 Jan. 27 at 11:20 AM
$TRAW this week we can touch 3,90 if all its ok
0 · Reply
Otherseal
Otherseal Jan. 26 at 11:57 PM
$TRAW 20 million market cap a joke either big bards grant or buyout No brainer
0 · Reply
Faberan22
Faberan22 Jan. 26 at 11:23 PM
$TRAW from the conpany's pr releases: a potential, effective prophylactic against the seasonal flu; a potential best-in-class anti-viral for covid, and a potential best-in-class (and stockpile ripe) pan anti- bird flu viral.
0 · Reply
mikesterz7
mikesterz7 Jan. 26 at 7:15 PM
$TRAW The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.
0 · Reply
Razor_BTC_F150
Razor_BTC_F150 Jan. 26 at 6:56 PM
$TRAW $8
0 · Reply
kyly2
kyly2 Jan. 26 at 6:54 PM
$TRAW Algo bueno ocurre
0 · Reply
topstockalerts
topstockalerts Jan. 26 at 6:54 PM
$TRAW One to watch closely today 👀. Momentum is building and price is holding strength. This setup is starting to form.
0 · Reply
Jbjb90
Jbjb90 Jan. 26 at 6:33 PM
$TRAW https://www.stocktitan.net/news/TRAW/traws-pharma-completes-enrollment-of-ratutrelvir-clinical-study-in-kfdj2x6pyjnl.html
0 · Reply
Dwarn2021
Dwarn2021 Jan. 26 at 6:31 PM
$TRAW keep running up to new ATH by summer!
0 · Reply
topstockalerts
topstockalerts Jan. 26 at 5:59 PM
$TRAW Looks like it wants higher prices. Buyers keep stepping in. This trend is still alive 📈.
0 · Reply
Schube1255
Schube1255 Jan. 26 at 5:53 PM
$TRAW 🤑
0 · Reply
Titi_Valk
Titi_Valk Jan. 26 at 5:51 PM
$TRAW #BARDA #H5N1 tivixavir morboxil update !!!
0 · Reply